Zilucoplan not checked
UCB Biopharma SRL · RA101495
FollowEvery change as it happens, and a Monday email
Trials
3 active
7 in total · 5 in the EU
What this is
- How it works
- Blocks part of the complement system, a branch of the immune system that can attack the body's own cells.Complement Inhibitor FDA class
- How it’s given
- “Zilucoplan will be administered subcutaneously to pediatric study participants”In the company’s words, NCT06435312 on ClinicalTrials.gov
- Tested for
- Generalized Myasthenia Gravis (2 trials)
- Main trialPhase 3
- “The purpose of this study is to assess the long-term safety and tolerability of an additional 52 weeks of Zilucoplan treatment administered by subcutaneous injection once daily in pediatric study participants”In the company’s words, NCT06435312 on ClinicalTrials.gov
- Other names
- RA101495
Other drugs for Generalized Myasthenia Gravis
- GefurulimabAlexion Pharmaceuticals, Inc. · Phase 3
- B007Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
- Descartes-08Cartesian Therapeutics · Phase 3
- TelitaciceptRemeGen · Phase 3
- Efgartigimodargenx · Phase 3
- TelitaciceptVor Biopharma · Phase 3
Coming up3
- 23 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 12 May 2027Phase 2/3 trial completes · ClinicalTrials.gov
- 26 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Enrolling by invitation | 26 Oct 2027 | An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | |
| Phase 2/3Recruiting | 12 May 2027 | A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | |
| Phase 1Recruiting | 23 Mar 2027 | A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women | |
| Phase 3Completed | 13 Mar 2024 | An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors | |
| Phase 3Completed | 28 Jan 2025 | A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis | |
| Phase 3Completed | 31 Jul 2026 | Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis | |
| Phase 1Completed | 26 Nov 2024 | A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026